FibroBiologics (FBLG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $7.00 price target on the stock.
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
FibroBiologics to Present at the BIO Investment & Growth Summit